Go Pro
→ Why major institutions are piling into this digital asset now (From Awesomely) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$1.05
-4.5%		$1.01
$0.76
▼
$3.31
$85.57M1.46629,873 shs715,982 shs
electroCore, Inc. stock logo
ECOR
electroCore
$8.99
-1.0%		$8.03
$4.41
▼
$10.95
$81.86M181,930 shs26,976 shs
iBio, Inc. stock logo
IBIO
iBio
$1.26
-3.1%		$1.42
$0.77
▼
$3.82
$83.60M1.29746,293 shs404,563 shs
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
$2.13
+0.9%		$4.22
$0.66
▼
$10.77
$21.35M-1.237.68 million shs12,576 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-4.55%-0.94%+1.94%-33.96%-50.70%
electroCore, Inc. stock logo
ECOR
electroCore
-0.99%-5.47%+0.33%-11.69%+76.97%
iBio, Inc. stock logo
IBIO
iBio
-3.08%-3.82%-10.00%-24.55%+125,999,900.00%
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
0.00%0.00%0.00%0.00%-73.67%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$1.05
-4.5%		$1.01
$0.76
▼
$3.31
$85.57M1.46629,873 shs715,982 shs
electroCore, Inc. stock logo
ECOR
electroCore
$8.99
-1.0%		$8.03
$4.41
▼
$10.95
$81.86M181,930 shs26,976 shs
iBio, Inc. stock logo
IBIO
iBio
$1.26
-3.1%		$1.42
$0.77
▼
$3.82
$83.60M1.29746,293 shs404,563 shs
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
$2.13
+0.9%		$4.22
$0.66
▼
$10.77
$21.35M-1.237.68 million shs12,576 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-4.55%-0.94%+1.94%-33.96%-50.70%
electroCore, Inc. stock logo
ECOR
electroCore
-0.99%-5.47%+0.33%-11.69%+76.97%
iBio, Inc. stock logo
IBIO
iBio
-3.08%-3.82%-10.00%-24.55%+125,999,900.00%
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
0.00%0.00%0.00%0.00%-73.67%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
2.14
Hold$7.50614.29% Upside
electroCore, Inc. stock logo
ECOR
electroCore
2.00
Hold$18.00100.22% Upside
iBio, Inc. stock logo
IBIO
iBio
3.13
Buy$5.00296.83% Upside
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest OBLN, CRDF, IBIO, and ECOR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/4/2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/19/2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/11/2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
William Blair logo
William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
8/5/2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/21/2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/2/2026
iBio, Inc. stock logo
IBIO
iBio
Chardan Capital logo
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$5.00
6/24/2026
electroCore, Inc. stock logo
ECOR
electroCore
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
6/24/2026
iBio, Inc. stock logo
IBIO
iBio
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$590K138.44N/AN/A$0.67 per share1.57
electroCore, Inc. stock logo
ECOR
electroCore
$32.03M2.53N/AN/A($0.21) per share-42.81
iBio, Inc. stock logo
IBIO
iBio
$100K810.31N/AN/A$1.54 per share0.82
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
$1.59M13.43N/AN/A$0.60 per share3.55
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$45.85M-$0.60N/AN/AN/A-7,885.43%-103.10%-75.52%11/5/2026 (Estimated)
electroCore, Inc. stock logo
ECOR
electroCore
-$13.97M-$1.66N/AN/AN/A-39.96%-1,956.38%-81.35%11/4/2026 (Estimated)
iBio, Inc. stock logo
IBIO
iBio
-$33.04M-$0.34N/AN/AN/AN/A-40.66%-35.78%11/11/2026 (Estimated)
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
-$12.33MN/AN/AN/AN/A-776.76%-161.38%-83.58%N/A

Latest OBLN, CRDF, IBIO, and ECOR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/28/2026Q4 2026
iBio, Inc. stock logo
IBIO
iBio
-$0.0655-$0.04+$0.0255-$0.07$0.08 millionN/A
8/11/2026Q2 2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$0.1196-$0.14-$0.0204-$0.14$0.06 million$0.10 million
8/6/2026Q2 2026
electroCore, Inc. stock logo
ECOR
electroCore
-$0.4218-$0.33+$0.0918-$0.33$9.49 million$9.45 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
N/AN/AN/AN/AN/A
electroCore, Inc. stock logo
ECOR
electroCore
N/AN/AN/AN/AN/A
iBio, Inc. stock logo
IBIO
iBio
N/AN/AN/AN/AN/A
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
N/A
3.30
3.30
electroCore, Inc. stock logo
ECOR
electroCore
N/A
1.21
1.00
iBio, Inc. stock logo
IBIO
iBio
N/A
7.85
7.85
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
N/A
1.86
1.86

Institutional Ownership

CompanyInstitutional Ownership
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
16.29%
electroCore, Inc. stock logo
ECOR
electroCore
26.74%
iBio, Inc. stock logo
IBIO
iBio
7.90%
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
18.64%

Insider Ownership

CompanyInsider Ownership
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
8.80%
electroCore, Inc. stock logo
ECOR
electroCore
7.80%
iBio, Inc. stock logo
IBIO
iBio
2.75%
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
8.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
2077.79 million70.95 millionOptionable
electroCore, Inc. stock logo
ECOR
electroCore
509.02 million8.31 millionNot Optionable
iBio, Inc. stock logo
IBIO
iBio
10064.31 million62.54 millionN/A
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
210.02 millionN/ANot Optionable

Recent News About These Companies

InterWest Management Partners X, LLC's Net Worth
August 4, 2024  |  benzinga.comhttps://www.benzinga.com/sec/insider-trades/0001460207/interwest-management-partners-x-llc
Spero Therapeutics Inc.
February 6, 2024  |  wsj.comhttps://www.wsj.com/market-data/quotes/SPRO
Intragastric Balloon Market Growth and Forecast till 2031
March 28, 2023  |  marketwatch.comhttps://www.marketwatch.com/press-release/intragastric-balloon-market-growth-and-forecast-till-2031-2023-03-28
Intragastric Balloons Market to Grow with a Significant CAGR During the forecast period 2022-2028| Exclusive Report Spread Across 149 Pages
August 17, 2022  |  marketwatch.comhttps://www.marketwatch.com/press-release/intragastric-balloons-market-to-grow-with-a-significant-cagr-during-the-forecast-period-2022-2028-exclusive-report-spread-across-149-pages-2022-08-17
Renovare Environmental Inc (RENO)
January 5, 2022  |  investing.comhttps://www.investing.com/equities/biohitech-global-news
Understanding Atara Biotherapeutics's Unusual Options Activity
August 10, 2021  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/21/08/22401123/understanding-atara-biotherapeuticss-unusual-options-activity

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cardiff Oncology stock logo

Cardiff Oncology NASDAQ:CRDF

$1.05 -0.05 (-4.55%)
Closing price 09/9/2026 04:00 PM Eastern
Extended Trading
$1.10 +0.04 (+4.29%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

electroCore stock logo

electroCore NASDAQ:ECOR

$8.99 -0.09 (-0.99%)
Closing price 09/9/2026 04:00 PM Eastern
Extended Trading
$9.01 +0.02 (+0.17%)
As of 09/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.

iBio stock logo

iBio NASDAQ:IBIO

$1.26 -0.04 (-3.08%)
Closing price 09/9/2026 04:00 PM Eastern
Extended Trading
$1.27 +0.01 (+1.19%)
As of 05:14 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

Obalon Therapeutics stock logo

Obalon Therapeutics NASDAQ:OBLN

Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. The company offers the Obalon Balloon System designed to provide weight loss in patients with obesity. Its Obalon Balloon System comprises of a swallowable capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement; the Obalon Touch Inflation Dispenser, which is a semi-automated, hand-held inflation device used to inflate the balloon once it is placed; and a disposable canister filled with mixture of gas. Obalon Therapeutics, Inc. was incorporated in 2008 and is headquartered in Carlsbad, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas